Multiple biological blockbusters, with cumulative sales of more than $50 billion, will be coming off-patent over next five years.
Celonic has been dedicated to the development and production of biosimilars for many years and is part of "The Biosimilars Group" expert network. Over the years, Celonic has developed strong know-how and expertise of biosimilar products and process development.
We are well positioned to give our clients a head start in the highly competitive biosimilars market.
What we do, we do extremely well: we develop cell lines and biotechnological production processes, we provide product batches for clinical trials and we guarantee quality at all stages of the process.
Most of our competitors rely on their own knowledge. So do we. With an added extra: we are involved in “The Biosimilars Group” expert network and have worked with other biosimilar experts to design a process for the development of biosimilar products. It takes into account the basic biosimilar concept, i.e. a drug’s high degree of similarity with drugs already on the market, from the initial development step to final production.